WOBURN, MA--(Marketwire - January 09, 2008) - Repromedix Corp., the leading national diagnostic laboratory for fertility testing, announces today the launch of Plan Ahead™, a new blood test that provides an assessment of a woman’s egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH with innovative and proprietary technology. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs which inevitably declines as a woman ages and her “biological clock ticks.” Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
